Jun 16, 2026 08:02AM
Jun 16, 2026 08:00AM
Jun 2, 2026 08:01AM
Jun 2, 2026 08:00AM
May 14, 2026 08:03AM
May 14, 2026 08:00AM
Mar 18, 2026 08:00AM Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Feb 17, 2026 08:02AM
Feb 17, 2026 08:00AM
Nov 13, 2025 08:00AM
Nov 10, 2025 08:01AM
Nov 10, 2025 08:00AM
Oct 28, 2025 08:01AM
Oct 28, 2025 08:00AM Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control
Oct 23, 2025 04:45PM
Oct 14, 2025 08:04AM
Oct 14, 2025 08:00AM
Sep 17, 2025 08:45AM
Sep 17, 2025 08:45AM
Aug 19, 2025 08:45AM
Aug 15, 2025 09:02AM Cingulate places CEO on administrative leave, names interim leadership
Aug 15, 2025 09:00AM
Aug 6, 2025 08:45AM
Aug 6, 2025 08:45AM
Jul 29, 2025 08:01AM
Jul 29, 2025 08:00AM
Jul 9, 2025 08:03AM
Jul 9, 2025 08:00AM Cingulate Appoints Nilay Patel as Chief Legal Officer to Support Growth ahead of New Drug Application
May 20, 2025 08:03AM
May 20, 2025 08:00AM
May 14, 2025 08:04AM
May 14, 2025 08:00AM
May 8, 2025 04:30PM
Apr 29, 2025 08:00AM
Apr 3, 2025 08:06AM Cingulate Inc (CING) Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301
Apr 3, 2025 08:00AM
Mar 26, 2025 05:00PM
Mar 4, 2025 09:02AM
Mar 4, 2025 09:00AM
Jan 7, 2025 07:30AM
Dec 23, 2024 07:30AM
Nov 7, 2024 07:30AM Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market
Sep 12, 2024 08:30AM
Aug 15, 2024 07:45AM
Aug 15, 2024 07:45AM
Aug 13, 2024 07:45AM
Jun 25, 2024 09:20AM
Jun 25, 2024 09:20AM
May 21, 2024 09:00AM FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD
May 8, 2024 07:00AM

323,580 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All